Coping with space motion sickness in Spacelab missions.
A substantial number of persons, around 75%, making their first transition into orbital flight will need to adapt to this unique environment. The two most powerful instruments in the prevention of space motion sickness reside in the selection process and in acquiring adaptation-prelaunch. Today, neither of these means is practical. One logical alternative is to administer preventative medication to all or none. One candidate drug is a high-potency transdermal therapeutic system (TTS)-scopolamine. This is marketed in the nature of a patch that is affixed to the skin behind the ear 12 hr before need and delivers scopolamine into the blood stream for three days. We are systematically evaluating all claims for its high potency and low side effects. We are also evaluating new antimotion sickness remedies and new combinations of homergic drugs.
Graybiel
A
A
Naval Aerospace Medical Research Laboratory, Pensacola, FL 32508, USA.
D000279:Administration, Cutaneous; D000337:Aerospace Medicine; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000627:therapeutic use; D003913:Dextroamphetamine / Q000008:administration & dosage / Q000627:therapeutic use; D004809:Ephedrine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011398:Promethazine / Q000008:administration & dosage / Q000627:therapeutic use; D012601:Scopolamine / Q000008:administration & dosage / Q000627:therapeutic use; D013026:Space Flight; D018489:Space Motion Sickness / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D014893:Weightlessness / Q000009:adverse effects*
D000932:Antiemetics; D000697:Central Nervous System Stimulants; D012601:Scopolamine; D011398:Promethazine; D004809:Ephedrine; D003913:Dextroamphetamine